Kornimate/medical-research-clean huggingface dataset:
biological and electrocardiographic biomarkers for risk stratification in hypertension.

Conditions: Hypertension

Summary: risk stratification of hypertensive patients includes assessment of traditional cardiovascular risk factors and subclinical target organ damages particularly left ventricular hypertrophy (lvh). lvh may routinely screened by transthoracic echocardiography by measuring the left ventricular mass (lvm). however, transthoracic echocardiography suffers from several pitfalls: poor reproducibility, technical limitations and unavailability at a first evaluation by general practitioners. other biomarkers may be particularly helpful in hypertension risk stratification. the amplitude of the r wave in avl lead is a simple validated ecg parameters of lvh and a strong predictor of cardiovascular events and mortality. plasma n-terminal pro brain natriuretic peptide (nt-probnp) is also strongly related to lvm and is an independent predictor of all-cause mortality in hypertension. the main objective of our study is to determine the additive prognostic value of r wave in avl and nt probnp on all-cause and cardiovascular mortality. secondary objectives are to determine the addition prognostic value of nt-probnp and r wave in avl combined in comparison to each marker taken into account this study will include 1600 patients who had a work-up of their hypertension in the cardiology department of croix-rousse hospital (hospices civils de lyon, lyon, france) from january 1997 to january 2014. their data will be collected in an access database; their vital status will be obtained by the insee unit cépidc.


Eligibility criteria:
* inclusion criteria: * \>18 years old * men or women * questionnaire completion and physical exam during their first stay in the cardiology department of from january 1997 to january 2014. * exclusion criteria: * patients refusal

Keywords: mortality hypertension left ventricular hypertrophy nt-probnp ecg transthoracic echocardiography
the impact of chiropractic on long covid-19

Conditions: Long COVID

Summary: the purpose of this waitlist-controlled, single-blind, one-way crossover, pilot trial is to evaluate the potential effects of \~8 weeks of chiropractic care on patient-reported fatigue and the autonomic nervous system in adults with long covid. this study will allow us to estimate the standard deviation of the primary endpoint in our population with which a formal power calculation for a future randomized, controlled trial can be performed.

after providing informed consent, participants will be placed on an 8-week waitlist followed by 8 weeks of chiropractic care. in-person assessments will occur 5 times: day 1, following 2-3 weeks on waitlist, following 8 weeks on waitlist, following 2-3 weeks of chiropractic care, and following 8 weeks of chiropractic care. patient-reported outcomes will additionally be sent prior to the first in-person assessment (day 0). assessments will include the following: 1. seated resting recording 2. sit-to-stand test 3. patient-reported outcome surveys each assessment will consist of the following recordings: 1. electroencephalography \[eeg\] 2. impedance cardiography \[icg\] 3. electrocardiogram \[ecg\]

Eligibility criteria:
participants will be individuals between the age of 18 and 65 who have tested positive for a covid-19 viral infection, or sars-cov-2 antibodies, not less than 120 days prior to their enrollment in the study. participants may also qualify if they have been medically diagnosed with long-covid by their medical provider, regardless of a positive test result. they must have a t score greater than or equal to 55 on the facit fatigue survey. they must also present with at least 1 of the following symptoms that cannot be explained by an alternative diagnosis, with symptom onset or exacerbation after contraction of covid-19. * body aches/joint pain * shortness of breath or difficulty breathing * persistent chest pain or pressure * recurrent fever, chills or night sweats * headache or dizziness * difficulty concentrating or focusing * memory problems * sleep problems * anxiety or depression * heart palpitations or tachycardia
oral abuse potential study of nalbuphine

Conditions: Nalbuphine; Opioid Abuse

Summary: the purpose of this study is to measure the effects of a drug called nalbuphine (an opioid drug) compared with the effects of hydromorphone (an opioid drug) and placebo (contains no active drug ingredients). the amount of nalbuphine levels in the blood will also be measured and the safety of the study drugs will be evaluated. this study has 2 parts: part a and part b.

this study will be a single-dose, randomized, double-blind, active- and placebo-controlled, double dummy, 2-part, 7-way crossover study to determine the abuse potential of orally administered nalbuphine solution and nalbuphine er intact tablets relative to hydromorphone solution and placebo, in non-dependent, recreational opioid users. the study will be conducted in a single clinical research unit (cru). the purpose of part a is to find the appropriate doses (a low, intermediate, and high dose) of nalbuphine solution to use in part b. part a of the study has two visits to the research clinic: a screening visit and dose selection visit. the visits will involve a 2-night stay (3 days total) in the research clinic. in the main study treatment phase in part b, the total estimated duration between each dose of study drug is approximately up to 7 days, of which the subject will spend 3 days/2 nights in the research clinic and approximately up to 4 days at home. the primary objective of the main study is to evaluate the abuse potential of orally administered nalbuphine solution and nalbuphine er intact tablets relative to hydromorphone solution (the active comparator) and placebo in non-dependent, recreational opioid users.

Eligibility criteria:
inclusion criteria: * healthy male or female subjects 18 to 55 years of age * current opioid users who have used opioids for recreational (non-therapeutic) purposes exclusion criteria: * self-reported substance or alcohol dependence (excluding nicotine and caffeine) * heavy smoker (≥ 20 cigarettes per day) and/or who is unable to abstain from smoking for at least 8 hours during the in clinic periods. * history or presence of clinically significant abnormality as assessed by physical examination, medical history, ecgs, vital signs, or laboratory values. * history or presence of any clinically significant illness * history of major mental illness that may affect the ability of the subject to participate in the study.

Keywords: nalbuphine abuse potential
minimal invasive surgery versus interlaminar decompression in lumbar canal stenosis

Conditions: Lumbar Spinal Stenosis

Summary: conventional open surgery has been shown to be an effective procedure for lcs decompression. minimally invasive surgery (mis) through tubular retractors is a recently introduced alternative procedure for decompression of lcs. the current study aims at evaluating the efficacy of minimally invasive surgery as a decompressive procedure in comparison to conventional open surgery for the treatment of patients with lcs.

lumbar canal stenosis (lcs) is defined as narrowing of the spinal canal, the vertebral foramina, and/or the lateral recesses, causing compression on the nearby neurologic structures. degenerative lcs is one of the most common reasons for old patients to undergo spinal surgery. neurogenic claudication is the most common symptom for lcs patients. the patients complain of pain or discomfort that radiates to the buttock, thigh and lower limb after walking for a certain distance, therefore leading to functional disability and decreased walking capacity. conservative management is the first line of treatment in the absence of progressive neurologic deficit or intractable pain, consisting of physical therapy, medications (analgesics, steroids) and pain management procedures. surgical intervention is recommended if the symptoms are persistent or worsening. various techniques are currently used for direct decompression of lcs. conventional open surgery involves laminectomy that has been shown to be an effective procedure for lcs decompression. however, wide laminectomies disturbs the stability of bony and ligamentous structures and may exacerbate preexisting spondylolisthesis. minimally invasive surgery (mis) through tubular retractors is a recently introduced alternative procedure for decompression of lcs. this technique avoids detachment of the paraspinal muscles and may promote preservation of stabilizing ligamentous and bony spinal structures. the current study aims at evaluating the efficacy of minimally invasive surgery as a decompressive procedure in comparison to conventional open surgery for the treatment of patients with lcs.

Eligibility criteria:
inclusion criteria: * all patient with lumbar canal stenosis from 18_70 years old exclusion criteria: * instability infection tumours of vertebrae

Keywords: minimally invasive surgery interlaminar decompression
a study to evaluate the safety and efficacy of oral contrast agent for sonography

Conditions: Unspecified Disorder of Stomach and Duodenum

Summary: the goal of this clinical trial is to verify the safety and efficacy of oral contrast agent for sonography produced by shandong baiduo medical instruments co., ltd.

the goal of this clinical trial is to verify the safety and efficacy of oral contrast agent for sonography produced by shandong baiduo medical instruments co., ltd. participants will ultrasound was administered with oral contrast agent for sonography and observed for 2 days. the investigators will compare oral contrast agent for sonography produced by huzhou east asia medical supplies co., ltd to see if the safety and efficacy of oral contrast agent for sonography produced by shandong baiduo medical instruments co., ltd

Eligibility criteria:
inclusion criteria: 1. subjects whose physicians recommend oral gastrointestinal ceus; 2. subjects aged 18-80 years; 3. the subject or guardian can understand the purpose of the study, voluntarily sign the informed consent, and agree to the clinical follow-up; exclusion criteria: 1. pregnant and lactating women; 2. subjects with dysphagia; 3. subjects suspected of gastric bleeding, gastrointestinal perforation, intestinal disorders or gastrointestinal obstruction; 4. subjects who are expected to receive surgery within 60 hours; 5. subjects who have received gastroscopy within 24 hours; 6. subjects deemed unsuitable for the study by the researcher; 7. subjects who have participated in other drug or device clinical trials and have not completed the expected primary endpoint follow-up of the clinical trials in which they participated.
laser in orthodontic leveling and alignment

Conditions: Dental Malocclusion

Summary: to evaluate the outcome of lllt regarding leveling and alignment of the mandibular anterior segment.

thirty patients, 18 females and 12 males, were included who had class i malocclusion with moderate mandibular crowding and an average age was 19.23 ± 3.1years.they were randomly divided into two parallel groups; a control group without laser intervention and a laser group which received lllt. all patients followed a non-extraction approach using one category of fixed appliance and matching conventional niti archwire sequence during 3 months observation period. in laser group, mandibular anterior teeth were irradiated by gallium aluminum arsenide semiconductor laser with 635 nm wavelength, 6.5j/cm2energy density, for 10 seconds at 10 points (0.2 j/point) on facial and lingual aspects. this protocol was started immediately after first wire insertion and then at days 3,7,14 of the first month and repeated for additional 2 months. in both groups, relief of mandibular crowding was assessed by little's irregularity index (lii) after 4 weeks (t1), after 8 weeks (t2), and after 12 weeks (t3) intervals. changes in lii scores were evaluated through scanned 3d models via software. in addition, the monthly rate of otm was calculated and compared. the level of significance was set at p ≤ 0.05.

Eligibility criteria:
inclusion criteria: * selection of participants was based on the following criteria: 1. the age range was from 15 to 25 years. 2. all permanent teeth erupted (3rd molar not included). 3. angle class i occlusion with normal facial proportions. 4. moderate crowding in the lower dental arch assessed by little's irregularity index that requires treatment with fixed appliance using non-extraction approach. 5. good oral and general health. 6. no previous or current periodontal disease. 7. no systemic disease or regular medication that could interfere and\\or affects orthodontic teeth movement. 8. no evidence of craniofacial anomalies, such as cleft lip and palate or previous history of trauma, bruxism or parafunction. 9. no previous orthodontic treatment. exclusion criteria: * the patients were excluded from the study if they have: 1. severe crowding that requires an extraction approach. 2. blocked-out teeth that didn't allow for placement of the bracket at the initial bonding appointment. 3. poor oral hygiene or periodontally compromised teeth. 4. relevant medical history that interferes with orthodontic treatment. 5. craniofacial anomalies or previous history of trauma, bruxism or parafunction. 6. previous orthodontic treatment. 7. the deep bite which interferes with orthodontic brackets placement.

Keywords: low-level laser therapy orthodontic tooth movement leveling and alignment little irregularity index.
pharmacokinetics and pharmacodynamics of ipx054 in subjects with parkinson's disease

Conditions: Idiopathic Parkinson's Disease

Summary: the objective is to compare the pharmacokinetics and pharmacodynamics of ipx054 and carbidopa-levodopa immediate-release tablets in subjects with idiopathic parkinson's disease who are currently being treated with a stable regimen of carbidopa-levodopa immediate-release tablets.

ipx054 contains two different drugs called levodopa and carbidopa in one tablet. * levodopa turns into a material called 'dopamine' in your brain. the dopamine helps to improve the symptoms of your parkinson's disease. * carbidopa belongs to a group of medicines called 'aromatic amino acid decarboxylase inhibitors'. it helps levodopa work more effectively by slowing the speed at which levodopa is broken down in your body.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic parkinson's disease * currently being treated with a stable dosage regimen of immediate-release carbidopa-levodopa for at least 3 months. * must experience at least 3 episodes of "wearing off" symptoms and an average of at least 2 hours of "off" time per day. exclusion criteria: * diagnosed with atypical parkinsonism * prior surgical interventions for parkinson's disease * glaucoma * undiagnosed skin lesion or history of melanoma * epilepsy or history of seizures

Keywords: ipx054 parkinson disease levodopa
randomized trial of erythropoietin during cerebral malaria

Conditions: Cerebral Malaria

Summary: malaria remains one of the most common life-threatening illnesses in the tropics with a dramatic toll of more than one million deaths each year. a majority of malaria cases are non-complicated and only few evolve towards severe malaria resulting from the combination of parasite-specific virulence factors and host inflammatory responses. cerebral malaria (cm) kills more than 1 million african children each year. cm carries a fatality rate of about 20% in adults, higher in children, despite timely and adequate chemotherapy. moreover, the more rapid clearance of parasitaemia with new antimalarial drugs is not associated with improved survival, suggesting the potential interest for adjunctive therapies in the early phase of the disease. cerebral malaria leading to seizure and coma is associated with severe intracranial hypertension caused by brain-swelling. recent imaging and post-mortem findings in adult cerebral malaria have confirmed the presence of diffuse cerebral oedema with thalamic and cerebellar white matter hypoattenuation, diffuse petechial hemorrhages and symmetric ischemic changes involving the thalamus and the cerebellum. however, the nature of the pathogenetic processes leading to cerebral malaria is incompletely understood but mechanisms linking cytokines with endothelial cells activation in the cerebral microvasculature have been recently stressed. the effect of new neuroprotective therapies has not yet been investigated, although the manifestations of cerebral malaria partly share features with neurological stroke or acute non-specific neurological disorders. the hormone erythropoietin (epo) is probably one of the more enthusiastic drugs in this area. epo is as a member of type i cytokine superfamily with multiple functions, including a prominent role for erythropoiesis and neuroprotection. systematically administered epo crosses the blood brain barrier via the abundant expression of epo receptors at brain capillaries, and acts as an anti-apoptotic and cytoprotective cytokine. moreover, epo prevents inflammation by inhibiting pro-inflammatory cytokines including tnfα, preserves endothelial cells integrity and prevents blood-brain barrier permeability. we propose a randomized clinical trial to investigate the safety and efficacy of epo in patients presenting cerebral malaria and hospitalized at gabriel toure hospital, bamako, mali, to reduce the incidence of premature death in hospitalized patients.


Eligibility criteria:
inclusion criteria: * children between 6 months and 14 years old * severe cerebral malaria due to plasmodium falciparum * coma (blantyre score \<3) * enlightened assessment exclusion criteria: * any case of participation refusal * presence of another obvious affection being able to explain the state of the patient * negative malaria test (thick smear / thin smear) * severe anaemia

Keywords: malaria treatment adjunctive erythropoietin survival
oral paclitaxel trial in recurrent and metastatic breast cancer as 1st line therapy

Conditions: Recurrent or Metastatic Breast Cancer

Summary: to compare and evaluate the efficacy and safety of liporaxel® solution (oral paclitaxel) and taxol® (iv paclitaxel) on recurrent or metastatic breast cancer.


Eligibility criteria:
key inclusion/exclusion criteria * histologically or cytologically confirmed to have recurrent, or metastatic breast cancer. * measurable disease (revised recist, version 1.1). * hormone receptor (er/pr) positive or negative, her2 negative. * subjects were eligible for the study regardless of their previous lines of endocrine therapy. * no prior chemotherapy is allowed in metastatic disease. * subjects who administrated the last dose of taxane class drug ≥12months ago as from the first administration day. * ecog performance status ≤1. * neuropathy grade \<2. * subjects with central nervous system metastasis should be excluded.

Keywords: recurrent breast cancer metastatic breast cancer mbc firstline chemotherapy paclitaxel liporaxel taxol
comparison of a single use (ambu ascope) and a reusable flexible optical scope for intubation through a supraglottic airway device (aura-i)

Conditions: General Anesthesia

Summary: in patient who are predicted to be difficult to intubate with a standard direct laryngoscope well use flexible optical intubation via a supraglottic airway devise (the ambu aura-i). patients are randomly assigner to a single- or a multiple- use flexible optical scope. we hypothesize that intubation is obtained equally effective with both types of flexible scopes


Eligibility criteria:
inclusion criteria: * asa physical status 1-3 and evaluated pre-operatively and found suitable for tracheal intubation with a flexible optical scope via the sad and scheduled for elective surgery/anesthesia and are conscious about their rights and consequences of participating in the study. * the patient must have one or two of the following predictors of difficult tracheal intubation: 1. modified mallampati score \> 2 (= "no parts of the uvula is visible") 2. a thyromental distance of less then or equal to 6.5 cms 3. combined movement in head and neck \< 90 degrees 4. mouth-opening less the 4 cm (but must be larger then 2.5 cm) 5. inability to protrude the teeth n the lower jaw beyond the upper incisors 6. bmi \> 40 combined with a neck-circumference \> 43 cms 7. upper-lip-bite-test \> 2 8. previous difficult intubation or laryngoscopy (if more then two criteria are fulfilled the patient should be considered intubated awake instead. . but the upper-lip-bite-test and the prognation-beyond the incisors test represents a similar thing, namely the inability to sub-luxate the lower jaw, the if both these findings are positive it is only considered as counting for one. exclusion criteria: * asa physical status 4 or 5 * contraindications for use of the sad * patients in whom intubation via a sad has previously failed * patients at risk of aspiration from the gastrointestinal channel * diseases in mouth, pharynx or larynx that precludes the use of a sad * patients in whom the cricothyroid membrane cannot be localized preanaesthetically * patients in whom the doctor making the pre-anaesthetic evaluation finds in need of an awake intubation * patients with possible creutzfeldt-jacobs disease or contraindication against the use of non-autoclavable equipment r risk of cross contamination with prions

Keywords: tracheal intubation
vitamin d supplementation and cd4 count in hiv-infected children

Conditions: HIV

Summary: to find out if vitamin d supplementing can lead to an improvement in immunological status in hiv-infected children as part of routine clinical care

the objective of this study is to determine the impact of vitamin d on immunological status in hiv-infected children as measured by cd4 count (cd4 percent). we will determine if vitamin d supplementation leads to a measurable change in cd4 count (cd4 percent) in hiv-infected children in the context of routine clinical care. specific study questions are: 1. does vitamin d supplementation lead to a change in cd4 percent (cd4 count) in hiv-infected children? 2. do the serum levels of the active form of vitamin d \[1, 25(oh)2d and 25(oh)d\] correlate with cd4 percent (cd4 count) in hiv-infected children?

Eligibility criteria:
inclusion criteria: * hiv-infected children as defined by ≥ 2 positive hiv dna pcrs and/or hiv cultures of blood for children less than 18 months of age, or by positive screening and confirmatory serologic testing in those older than 18 months of age * stable hiv disease, defined by the absence of change in hiv clinical or immunologic category during the preceding 6 month period, prior to commencing the study * age 3 years through 18 years * voluntary informed consent exclusion criteria: * any antiretroviral medication change in the 6 months prior to the study, or any anticipated antiretroviral medication change during the duration of the study * active participation in another treatment trial * serum calcium \< 2mmol/l at baseline

Keywords: vitamin d hiv-infected children cd4 count